Timing of intracoronary bone-marrow-derived stem cell transplantation after ST-elevation myocardial infarction

被引：56

作者：

Bartunek J. ^{[1
]}

Wijns W. ^{[1
]}

Heyndrickx G.R. ^{[1
]}

Vanderheyden M. ^{[1
]}

机构：

[1] Cardiovascular Center, OLV Ziekenhuis, 9300 Aalst

来源：

Nature Clinical Practice Cardiovascular Medicine | 2006年 / 3卷 / Suppl 1期

关键词：

Acute myocardial infarction; Intracoronary stem cell therapy; Timing;

D O I：

10.1038/ncpcardio0417

中图分类号：

学科分类号：

摘要：

It is still unclear whether the timing of intracoronary stem cell therapy affects the therapeutic response in patients with reperfused myocardial infarction. The natural course of healing the infarction and the presence of putative homing signals within the damaged myocardium appear to favor cell engraftment during the transendothelial passage in the early days after reperfusion. However, the adverse inflammatory environment, with its high oxidative stress, might be deleterious if cells are administered too early after reperfusion. In addition, current studies use mostly unfractionated cells and it remains to be addressed whether specific cell types, and their enrichment, would be better suited to augmenting the recovery at later time points. Here we highlight several aspects of the timing of intracoronary stem cell therapy and focus on time-related questions that are relevant to the design of future experimental and basic studies. © 2006 Nature Publishing Group.

引用

页码：S52 / S56

页数：4

共 22 条

[1]

Strauer B.E., Et al., Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans, Circulation, 106, pp. 1913-1918, (2002)

[2]

Assmus B., Et al., Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI), Circulation, 106, pp. 3009-3017, (2002)

[3]

Fernandez-Aviles F., Et al., Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction, Circ Res, 95, pp. 742-748, (2004)

[4]

Wollert K.C., Et al., Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial, Lancet, 364, pp. 141-148, (2004)

[5]

Bartunek J., Et al., Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recant myocardial infarction. Feasibility and safety, Circulation, 112, SUPPL. 9, (2005)

[6]

Antman E.M., Braunwald E., ST elevation myocardial infarction: Pathology, pathophysiology and clinical features, Braunwald's Heart Disease, pp. 1141-1165, (2005)

[7]

Wojakowski W., Et al., Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells and mononuclear cells expressing early cardiac, muscle and endothelial markers into peripheral blood in patients with acute myocardial infarction, Circulation, 110, pp. 3213-3220, (2004)

[8]

Massa M., Et al., Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction, Blood, 105, pp. 199-206, (2005)

[9]

Nian M., Et al., Inflammatory cytokines and postmyocardial infarction remodeling, Circ Res, 94, pp. 1543-1553, (2004)

[10]

Frangogiannis N.G., Et al., The inflammatory response in myocardial infarction, Cardiovasc Res, 53, pp. 31-47, (2002)

← 1 2 3 →